Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 5/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | PIM1 | P11309 | 9/20 | 0.68 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.68 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | MAOB | P27338 | 2/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.62 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.62 |
| ▸ | CLK1 | P49759 | 1/20 | 0.62 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424616 | 1.00 | CISD1 (1.00) | CISD1MAOAGSK3BTDP1PIM1 | |
| SCHEMBL1250001 | 1.00 | CISD1 (1.00) | CISD1MAOAGSK3BTDP1PIM1 | |
| SCHEMBL23094478 | 0.84 | CISD1 (0.73) | CISD1MAOAGSK3BTDP1PIM1 | |
| SCHEMBL8310397 | 0.84 | CISD1 (1.00) | CISD1MAOAGSK3BTDP1RAB9A | |
| SCHEMBL8310399 | 0.84 | CISD1 (1.00) | CISD1MAOAGSK3BTDP1RAB9A | |
| SCHEMBL14860989 | 0.82 | TDP1 (1.00) | CISD1MAOAGSK3BTDP1HPGD | |
| SCHEMBL14860991 | 0.82 | TDP1 (1.00) | CISD1MAOAGSK3BTDP1HPGD | |
| SCHEMBL14860992 | 0.82 | TDP1 (1.00) | CISD1MAOAGSK3BTDP1HPGD | |
| SCHEMBL23094695 | 0.82 | GSK3B (1.00) | CISD1MAOAGSK3BTDP1PIM1 | |
| SCHEMBL1125013 | 0.81 | PIM1 (0.72) | CISD1MAOAGSK3BTDP1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947206-B2 | cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210038566-A1 | USE OF MODULATORS OF NEET PROTEINS FOR THE TREATMENT OF INFECTION | ENYO PHARMA (FR) | 2021-02-11 | — | — | US | disclosed |
| WO-2019154958-A1 | USE OF MODULATORS OF NEET PROTEINS FOR THE TREATMENT OF INFECTION | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051185-A1 | Chemical Compounds 251 | ASTRAZENECA AB (SE) | 2015-02-19 | — | — | US | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-8901307-B2 | Chemical compounds 251 | ASTRAZENECA AB (SE) | 2014-12-02 | — | — | US | disclosed |
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | ASTRAZENECA AB (SE) | 2011-09-08 | — | — | US | disclosed |
| WO-2006005683-A1 | PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
| EP-1610812-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2006-01-04 | — | — | EP | disclosed |
| EP-1605967-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| EP-1585541-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| EP-1429763-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| WO-2003027081-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218182-A1 | CHEMICAL COMPOUNDS 251 | PIM1, PIM3, PIM2 | CISD1 4266/4885MAOA 2538/4885GSK3B 82/4885 |
| US-10947206-B2 | cGAS antagonist compounds | CGAS, STING1, GLS2 | CISD1 3416/4885MAOA 825/4885GSK3B 1868/4885 |
| US-20210038566-A1 | USE OF MODULATORS OF NEET PROTEINS FOR THE TREATMENT OF INFECTION | PEBP1, ELANE, MME | CISD1 2695/4885MAOA 3212/4885GSK3B 3449/4885 |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | IAPP, IRS1, GPR119 | CISD1 591/4885MAOA 4704/4885GSK3B 4545/4885 |
| US-20150051185-A1 | Chemical Compounds 251 | PIM1, PIM3, PIM2 | CISD1 4302/4885MAOA 2767/4885GSK3B 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.